mepenzolate bromide
Trade name: cantil
Approved
Nov 14, 1956
Mepenzolate is a postganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. It specifically antagonizes muscarinic receptors. Mepenzolate is marketed under the brand name CANTIL. CANTIL is indicated for use as adjunctive therapy in the treatment of peptic ulcer. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Timeline
1950s
- Nov 14, 1956
Sanofi-Aventis — Earliest FDA Approval
- Nov 14, 1956
Sanofi-Aventis — NDA Secondary Org
- Nov 14, 1956
Sanofi-Aventis — NDA Organization
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M1ANTAGONIST
CHRM1 antagonist
Role in regulating gastric secretion, M1 likely involved
- Muscarinic acetylcholine receptor M3ANTAGONIST
CHRM3 antagonist
Role in regulating gastric secretion, M3 likely involved
Approval history
- approvedNov 14, 1956
Chemistry & pharmacology
SMILES
C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1- Mol. weight
- 340.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL524004 ↗
- WikipediaMepenzolate ↗
- NCATSONW3LB39P7 ↗
- ChEMBLCHEMBL1724 ↗
Also known as
- aventis behring brand of mepenzolate bromide
- cantil
- cantil
- cantil
- cantil
- glycophenylate
- glycophenylate
- mepenzolate
- mepenzolate
- mepenzolate
- mepenzolate
- mepenzolate
- mepenzolate
- mepenzolate
- mepenzolate
- mepenzolate
- mepenzolate bromide
- mepenzolate bromide
- mepenzolate bromide
- mepenzolate bromide
- mepenzolate bromide
- mepenzolate bromide, (+-)-isomer
- mepenzolate iodide
- mepenzolate methylbromide
- mepenzolate methylbromide
- mepenzolic acid
- mepenzolic acid
- mepenzolic acid
- mepenzolic acid, bromine salt
- mepenzolic acid, bromine salt, 1-(methyl-(14)c)-labeled
- mepenzolon
- mepenzolone bromide
- mepenzolone bromide
- n-methyl-3-piperidylbenzilate methyl bromide
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Sanofi-Aventis | For profit | NDA2 | Nov 14, 1956 |
| Sanofi-Aventis | For profit | NDA | Nov 14, 1956 |